CHMP rec­om­mends Ab­b­Vie's mi­graine drug, GSK's ane­mia treat­ment

The EMA’s Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) rec­om­mend­ed this week that the Eu­ro­pean Com­mis­sion au­tho­rize two new treat­ments for mi­graine and chron­ic kid­ney dis­ease-as­so­ci­at­ed ane­mia.

The com­mit­tee grant­ed a pos­i­tive rec­om­men­da­tion to Ab­b­Vie’ Qulip­ta, known in Eu­rope as Aquip­ta, to pre­vent mi­graines in adults with at least four “mi­graine days” in a month. Ab­b­Vie VP of neu­ro­science de­vel­op­ment Dawn Carl­son told End­points News that CHMP’s opin­ion was based on two Phase III stud­ies test­ing 60 mg of the drug, al­so known as ato­gepant, once dai­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER